PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.52 - 1.58
1.19 - 3.37
354.5K / 984.1K (Avg.)
-1.64 | -0.94
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
35.46%
Revenue growth above 1.5x ENPH's 3.42%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
-171.55%
Negative gross profit growth while ENPH is at 15.36%. Joel Greenblatt would examine cost competitiveness or demand decline.
-922.43%
Negative EBIT growth while ENPH is at 63.85%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-930.10%
Negative operating income growth while ENPH is at 63.85%. Joel Greenblatt would press for urgent turnaround measures.
-948.31%
Negative net income growth while ENPH stands at 57.11%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-946.15%
Negative EPS growth while ENPH is at 57.55%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-943.59%
Negative diluted EPS growth while ENPH is at 57.55%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.00%
Share reduction more than 1.5x ENPH's 0.97%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
0.07%
Diluted share reduction more than 1.5x ENPH's 0.97%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
279.96%
OCF growth above 1.5x ENPH's 13.12%. David Dodd would confirm a clear edge in underlying cash generation.
19.65%
Positive FCF growth while ENPH is negative. John Neff would see a strong competitive edge in net cash generation.
58.55%
Positive 10Y revenue/share CAGR while ENPH is negative. John Neff might see a distinct advantage in product or market expansion over the competitor.
-17.44%
Both face negative 5Y revenue/share CAGR. Martin Whitman would suspect macro headwinds or obsolete product offerings across the niche.
-46.77%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
23.68%
10Y OCF/share CAGR under 50% of ENPH's 99.54%. Michael Burry would worry about a persistent underperformance in cash creation.
-71.13%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-63.14%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-6403.77%
Negative 10Y net income/share CAGR while ENPH is at 99.45%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-234.35%
Negative 5Y net income/share CAGR while ENPH is 81.91%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-497.53%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
-91.06%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
-87.75%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-91.23%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.19%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
-13.57%
Inventory is declining while ENPH stands at 2.70%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-15.77%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-74.09%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-24.22%
We’re deleveraging while ENPH stands at 4.50%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-4.20%
Our R&D shrinks while ENPH invests at 10.96%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
6.03%
SG&A growth well above ENPH's 0.27%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.